InMed Pharmaceuticals Inc. (INM) intrinsic value & 10-year financials
InMed Pharmaceuticals Inc. (INM) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue grew 26.9% a year to $4.9M, with an average return on invested capital of -1418.4%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.32
- Market cap
- $1.3M
- Revenue (FY2025)
- $4.9M
- Revenue growth (7-yr CAGR)
- 26.9%
- ROIC (10-yr avg)
- -1418.4%
- Free cash flow (FY2025)
- —
INM 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $4.9M | -$8.2M | -$8.36 | — | — | -274.6% |
| FY2024 | $4.6M | -$7.7M | -$1.01 | -$7.0M | — | -237.2% |
| FY2023 | $1.4M | -$7.9M | -$1.08 | -$7.4M | -581.9% | -245.1% |
| FY2022 | $1.4M | -$18.6M | -$11.06 | -$15.6M | -1361.9% | -1064.7% |
| FY2021 | $1.9M | -$10.2M | -$12.65 | -$9.8M | -535.9% | -3899.9% |
| FY2020 | — | -$8.9M | — | -$7.4M | — | -2789.0% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
InMed Pharmaceuticals Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
InMed Pharmaceuticals Inc. has historically struggled to out-earn its cost of capital, averaging just -14.2% ROIC.
InMed Pharmaceuticals Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, InMed Pharmaceuticals Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-277.68 per share.